Katie Montgomery
Family · Corpus Christi, TXNPI 1841845286
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 78.8% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $16,764 and has fallen 87.2% since, to $2,151 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $86.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$23K
- AstraZeneca$974
- Bayer$888
- Aurinia Pharma U.S., Inc.$693
- Calliditas Therapeutics US Inc.$530
- Corcept Therapeutics$489
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$14,09349%
- Travel & lodging$5,91420%
- Food & beverage$8,90031%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 96 | $22,796 |
| AstraZeneca | 25 | $974 |
| Bayer | 29 | $888 |
| Aurinia Pharma U.S., Inc. | 55 | $693 |
| Calliditas Therapeutics US Inc. | 24 | $530 |
| Corcept Therapeutics | 14 | $489 |
| Boehringer Ingelheim | 15 | $369 |
| Fresenius USA Marketing, Inc. | 16 | $242 |
| Vifor Pharma, Inc. | 14 | $236 |
| Novo Nordisk | 4 | $194 |
| Nevro Corp. | 3 | $157 |
| Outset Medical Inc | 2 | $130 |
| Melinta Therapeutics, LLC | 2 | $129 |
| Idorsia Pharmaceuticals US Inc | 1 | $124 |
| Dexcom, Inc. | 1 | $122 |
| Novartis | 5 | $109 |
| Xeris Pharmaceuticals, Inc. | 5 | $107 |
| Sanofi | 1 | $103 |
| Akebia Therapeutics Inc | 1 | $86 |
| Travere Therapeutics, Inc. | 5 | $83 |
| GSK | 3 | $65 |
| Mallinckrodt Hospital Products Inc. | 3 | $63 |
| Ardelyx, Inc. | 3 | $59 |
| Terumo Medical Corporation | 1 | $56 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $39 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,939 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 19 | $539,407 |
| FarxigaDapagliflozin Propanediol | 152 | $119,911 |
| KerendiaFinerenone | 90 | $80,342 |
| VeltassaPatiromer Calcium Sorbitex | 25 | $35,543 |
| Sevelamer Carbonate | 26 | $6,983 |
| DapagliflozinDapagliflozin Propanediol | 14 | $6,085 |
| Mycophenolate Mofetil | 31 | $5,296 |
| Nebivolol Hcl | 19 | $1,383 |
| Furosemide | 155 | $1,078 |
| Allopurinol | 114 | $858 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 73 | $813 |
| Finasteride | 59 | $813 |
| Tamsulosin Hcl | 67 | $738 |
| Calcitriol | 41 | $628 |
| Amlodipine Besylate | 83 | $533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $22,796 | $539,40719 claims |
| AstraZenecaFarxiga | $974 | $119,911152 claims |
| BayerKerendia | $888 | $80,34290 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Corpus Christi
- Stephanie RodriguezCorpus Christi$159K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.